Today: 29 April 2026
Gold price today dips on year-end profit-taking as dollar firms; $5,000 in view for 2026
31 December 2025
2 mins read

Gold price today dips on year-end profit-taking as dollar firms; $5,000 in view for 2026

NEW YORK, December 31, 2025, 03:47 ET — Market closed

  • Spot gold slipped 0.4% to $4,329.12/oz in thin year-end trading, after Friday’s record high.
  • U.S. gold futures fell 1%, while silver slid 5.6% as investors booked profits into the year-end.
  • Gold-backed ETFs and miner stocks are set to take their cue from bullion when U.S. trading resumes.

Gold prices edged lower on Wednesday as year-end profit-taking and a firmer dollar cooled the latest surge, with spot gold down 0.4% at $4,329.12 an ounce by 2:56 a.m. ET. U.S. gold futures for February fell 1% to $4,340.90, pulling back from Friday’s record $4,549.71 even as bullion remains up more than 60% in 2025; spot silver slid 5.6% to $72.20. “Maybe towards the end of the first quarter, we could see gold test $5,000,” said Ilya Spivak, head of global macro at Tastylive. Reuters

The late-year wobble matters because bullion has turned into a centerpiece macro trade in 2025, and portfolios tend to rebalance hard into calendar turns. Those flows can force quick repositioning in metals-linked funds and mining shares when the U.S. session reopens.

Gold is a “safe haven” — an asset investors buy when they want protection against shocks — but it still trades like a rates market at times. With holiday liquidity thin, small moves in the dollar and bond yields can swing prices more than usual.

Treasury yields have remained a key pressure point because higher yields raise the opportunity cost of holding gold, which pays no interest. The U.S. 10-year yield rose to 4.13% on Dec. 30, Trading Economics data showed.

Gold’s pullback followed sharp two-way trade this week, after a bout of profit-taking knocked prices off record highs and then drew buyers back in. Spot gold rose 0.8% to $4,364.70 on Tuesday after Monday marked its biggest daily percentage loss since Oct. 21, Reuters reported, as traders digested a divided Federal Reserve debate over the December rate cut.

The broader backdrop remains supportive, with investors still weighing the outlook for U.S. monetary easing, central bank demand and flows into funds that hold physical bullion. Investing.com said gold was still set for a gain of more than 60% in 2025, despite the late-year drift lower.

In gold-linked stocks, SPDR Gold Shares (GLD) — a U.S.-listed exchange-traded fund that trades like a stock while holding bullion — last traded at $398.89, up 0.07%, according to Barchart data.

Among miners, traders often use the big names as a levered proxy for the metal because profits can rise faster than gold when prices climb. Barrick Mining (B) last traded at $44.24, while its last after-hours price was $43.63, down 1.38%, Investing.com data showed.

Before the next session, investors will keep an eye on how quickly markets reprice the path for U.S. rates, a key driver for the dollar and real yields. The Federal Reserve’s next policy meeting runs Jan. 27–28, according to the central bank’s calendar.

The near-term macro calendar also matters because data can jolt rate expectations quickly at the start of a new year. The U.S. Employment Situation report for December 2025 is scheduled for Jan. 9 at 8:30 a.m. ET, the Bureau of Labor Statistics shows.

Stock Market Today

  • Align Technology Beats Q1 Sales Estimates, Reports $1.04 Billion Revenue
    April 29, 2026, 4:41 PM EDT. Align Technology (NASDAQ:ALGN) reported a strong Q1 CY2026 with 6.2% year-on-year sales growth to $1.04 billion, exceeding Wall Street revenue estimates by 1.8%. Adjusted earnings per share came in at $2.58, 12.8% above analyst consensus. The company's operating income also beat expectations by 11.1%, driven by solid operating margins of 21.5%. Despite these gains, Align projected next quarter revenue around $1.05 billion, aligning with market forecasts. The company's five-year annualized revenue growth of 7.8% outpaces healthcare sector averages, but recent two-year growth has slowed to 2.3%, raising concerns about demand trends. Analysts project modest growth going forward, around 3%, indicating cautious investor sentiment on new product impact.

Latest article

Nebius Stock Jumps as Meta’s AI Spending Reset Puts $27 Billion Deal in Focus

Nebius Stock Jumps as Meta’s AI Spending Reset Puts $27 Billion Deal in Focus

29 April 2026
Nebius Group N.V. shares rose 5.3% to $142.73 Wednesday as Meta Platforms raised its 2026 capital spending forecast by up to $10 billion, citing higher data center costs. Nebius has a contract to supply Meta with up to $27 billion in AI cloud capacity. Fourth-quarter 2025 revenue jumped 547% to $227.7 million, but the company reported a net loss of $249.6 million.
Phillips 66 Stock Jumps as Surprise Profit Shows Refining Margins Are Back in Focus

Phillips 66 Stock Jumps as Surprise Profit Shows Refining Margins Are Back in Focus

29 April 2026
Phillips 66 reported an adjusted first-quarter profit of $200 million, or 49 cents per share, beating analyst forecasts of a loss. Strong refining margins and 95% plant utilization offset $839 million in hedge-related losses. Shares rose over 6% after the results. The company also completed its acquisition of Lindsey Oil Refinery assets in the UK.
Extreme Networks Stock Jumps as Q3 Earnings Beat Puts Cisco, HPE Rivals in Focus

Extreme Networks Stock Jumps as Q3 Earnings Beat Puts Cisco, HPE Rivals in Focus

29 April 2026
Extreme Networks shares surged 28% after reporting fiscal Q3 revenue of $316.9 million, up 11%, and non-GAAP earnings of 26 cents per share, both above estimates. The company forecast Q4 revenue of $330–$335 million, topping FactSet’s $326.9 million estimate. SaaS annual recurring revenue rose 28.6% to $236.4 million. Net income climbed to $10.6 million from $3.5 million a year earlier.
Al-Arafah Islami Bank, Provati Insurance sign deal to digitise premium payments in Bangladesh
Previous Story

Al-Arafah Islami Bank, Provati Insurance sign deal to digitise premium payments in Bangladesh

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades
Next Story

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Go toTop